Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Steen Husted; Raffaele de Caterina; Felicita Andreotti; Harald Arnesen; Fedor Bachmann; Kurt Huber; Jørgen Jespersen; Steen Dalby Kristensen; Gregory Y. H. Lip; Joao Morais; Lars H. Rasmussen; Agneta Siegbahn; Robert F. Storey; Jeffrey I. Weitz; the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease; on behalf of

doi:10.1160/TH14-03-0228

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 111(05): 781-782
DOI: 10.1160/TH14-03-0228

Editorial

Schattauer GmbH

Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel

Steen Husted

¹Medical Department, Hospital Unit West, Denmark

,

Raffaele de Caterina

²Institute of Cardiology & Center of Excellence on Aging, G. d’Annunzio University, Chieti, Italy

,

Felicita Andreotti

³Department of Cardiovascular Science, Catholic University, Rome, Italy

,

Harald Arnesen

⁴Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway

,

Fedor Bachmann

⁵University of Lausanne, Switzerland

,

Kurt Huber

⁶3rd Department of Medicine, Wilhelminenspital, Vienna, Austria

,

Jørgen Jespersen

⁷Unit for Thrombosis Research, Institut of Public Health, University of Southern Denmark, Denmark

,

Steen Dalby Kristensen

⁸Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

,

Gregory Y. H. Lip

⁹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

,

Joao Morais

¹⁰Cardiology Division, Santo Andre´s Hospital, Leiria, Portugal

,

Lars H. Rasmussen

¹¹Thrombosis Research Centre, Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark and Department of Cardiology, Aalborg University Hospital, Denmark

,

Agneta Siegbahn

¹²Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

,

Robert F. Storey

¹³Department of Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom

,

Jeffrey I. Weitz

¹⁴Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Canada McMaster University, Hamilton, Canada

,

the ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease

› Institutsangaben

Abstract

Note: The editorial process for this paper was fully handled by Prof Christian Weber, Editor in Chief.

Volltext

Referenzen

References
1 Gallego P, Roldan V, Marin F. et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
2 De Caterina R, Husted S, Wallentin L. et al. Vitamin k antagonists in heart disease: Current status, perspectives (section iii). Position paper of the esc working group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013; 110: 1087-1107.
3 De Caterina R, Husted S, Wallentin L. et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: Esc working group on thrombosis-task force on anticoagulants in heart disease position paper. J Am Coll Cardiol 2012; 59: 1413-1425.
4 Ogilvie IM, Newton N, Welner SA. et al. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med 2010; 123: 638-645. e634.
5 Wilke T, Groth A, Mueller S. et al. Oral anticoagulation use by patients with atrial fibrillation in germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012; 107: 1053-1065.
6 De Caterina R, Husted S, Wallentin L. et al. General mechanisms of coagulation, targets of anticoagulants (section i). Position paper of the esc working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 569-579.
7 Weitz JI, Eikelboom JW, Samama MM. New anti-thrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012; 141: e120S-151S.
8 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385-1413.
9 Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol 2013; 26: 191-202.
10 Heidbuchel H, Verhamme P, Alings M. et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013; 15: 625-651.
11 Lip GYH, Camm AJ, Hylek EM. et al. Non-Vitamin K Antagonist Oral Anticoagulants: An Appeal for Consensus on Terminology. Chest. 2014 Epub ahead of print
12 De Caterina R, Husted S, Wallentin L. et al. Parenteral anticoagulants in heart disease: Current status, perspectives (section ii). Position paper of the esc working group on thrombosis - task force on anticoagulants in heart disease. Thromb Haemost 2013; 109: 769-786.